M Pharmaceutical Inc.
CNSX : MQ
OTCQB : MPHMF
FRANKFURT : T3F2

M Pharmaceutical Inc.

September 03, 2015 13:09 ET

M Pharmaceutical to Present at SeeThruEquity Conference in New York

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 3, 2015) - M Pharmaceutical, Inc. (CSE:MQ)(OTCQB:MPHMF)(FRANKFURT:T3F2), (the "Company"), a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications, today announced that the company will present at the SeeThruEquity Fall Microcap Investor Conference on September 10, 2015, at 10:00am local time at the Convene Grand Central in New York, NY.

Matthew B. Lehman, the Company's new Chief Executive Officer, will provide a corporate overview and development update on Company's technology. This will be a strong opportunity for the Company to showcase its development plan to a targeted audience of institutional and sophisticated investors. A copy of Mr. Lehman's presentation will be made available on the Company's website prior to the event.

About SeeThruEquity Fall Microcap Conference

SeeThruEquity is committed to providing unbiased research for companies under $1 billion in market capitalization and hosts well respected quarterly investor conferences for small and microcap companies. Since its inception in 2011, the firm has grown to over 125 companies under coverage and has successfully hosted 16 investor conferences. This conference will bring together over 40 presenting companies and over 400 attendees. The guests will enjoy detailed presentations, targeted one-on-one meetings, and numerous networking opportunities.

About M Pharmaceutical Inc.

Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The Company has exclusive rights to three technologies: (1) Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity; (2) Trimtec, gastrointestinal neurostimulators implanted laparoscopically for the treatment of obesity and gastroparesis without permanent anatomical modification of the stomach; and (3) eMosquito wearable blood monitor, for automatic and autonomous monitoring of blood glucose by diabetics.

M Pharmaceutical trades on the Canadian Securities Exchange (CSE) under the ticker symbol "MQ" as well as on the OTCQB as "MPHMF" and FWB (Frankfurt Stock Exchange) as "T3F2."

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the eMosquito, Trimeo and Trimtec biomedical technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company's filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: Trimeo, Trimtec, and eMosquito are investigational devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.

Contact Information